Raphael Ognar
President & CEO, Co-founder,
NKILT Therapeutics
With 3 decades in oncology and cell therapy, Raphaël is now putting all of it into a company he co-founded: NKILT Therapeutics, where he serves as President, CEO, and Board Chairman.
His path there was deliberate. At Novartis Oncology, he led global Marketing & Drug Development teams, bringing 2 drugs to approval in multiple myeloma and lung cancer. Stints at Celgene and Bristol-Myers Squibb followed, with corporate strategy roles that put him in the room with C-suites and boards. Since 2018, he has advised early-stage Immuno-oncology, cell therapy and digital health companies through his executive strategy & operations consultancy, building strategy, lab & operations across several start-ups.
This is when he created NKILT, an allogeneic NK cell therapy platform on fully owned technology. The company is on track for two INDs across hematologic and solid tumors, with clinical development planned for 2028 and a Series A expected late 2027. Raphaël also sits on the ACS New York board, the Phacilitate Advanced Therapy advisory board and is faculty at the Advanced Therapy Think Tank.
Outside work, he climbs, plays in his family rock band, enjoys his rescued Pitbulls & is a devoted wine fanatic.
His path there was deliberate. At Novartis Oncology, he led global Marketing & Drug Development teams, bringing 2 drugs to approval in multiple myeloma and lung cancer. Stints at Celgene and Bristol-Myers Squibb followed, with corporate strategy roles that put him in the room with C-suites and boards. Since 2018, he has advised early-stage Immuno-oncology, cell therapy and digital health companies through his executive strategy & operations consultancy, building strategy, lab & operations across several start-ups.
This is when he created NKILT, an allogeneic NK cell therapy platform on fully owned technology. The company is on track for two INDs across hematologic and solid tumors, with clinical development planned for 2028 and a Series A expected late 2027. Raphaël also sits on the ACS New York board, the Phacilitate Advanced Therapy advisory board and is faculty at the Advanced Therapy Think Tank.
Outside work, he climbs, plays in his family rock band, enjoys his rescued Pitbulls & is a devoted wine fanatic.
Sessions
-
08-Sep-2026Theatre 2 (Rubi)Panel: Funding the future of advanced therapies: Traditional capital vs new models of biotech financing
-
08-Sep-2026Roundtable: Data that unlocks capital: What investors actually want to see at seed and Series A and what doesn’t move the needle
-
21-Jan-2027Theatre 1Session 6: Do we need to rethink our approach to overcoming resistance in the TME?